Results 81 to 90 of about 63,819 (300)

Urticaria pigmentosa in adult [PDF]

, 2012
La urticaria pigmentosa es una de las formas más comunes de las mastocitosis, las cuales corresponden a una serie de procesos caracterizados por un aumento anormal de los mastocitos en diversos órganos y tejidos corporales.
Gelvis Rodríguez, José A., Torres Gómez, Vanessa, Cala Durán, Julián Camilo, Mosquera Sánchez, Hernando, Avila Rueda, Jhon Alexander   +4 more
core  

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Cold-induced urticaria associated with type I cryoglobulinemia, successfully treated with rituximab

JAAD Case Reports, 2022
Leonie C. Stroet, MD, Maud A.W. Hermans, MD, PhD, M. Maurer, MD, Martijn B.A. van Doorn, MD, PhD   +3 more
doaj   +1 more source

¿Requiere cambios la clasificación actual de urticaria crónica?

Revista Alergia México, 2018
Antecedentes: La urticaria se caracteriza por la aparición de erupciones pruriginosas asociadas en algunos casos con angioedema. Se clasifica en aguda y crónica según la duración de los síntomas.
July Ospina-Cantillo, Liliana Guevara-Saldaña, Ricardo Cardona   +2 more
doaj  

Chronic Spontaneous Urticaria and Comorbidities

77107Chronic spontaneous urticaria (CSU) is a common and debilitating disease, which frequently coexists with other diseases, i.e., comorbidities. Some comorbidities, e.g., autoimmune diseases, are more common in CSU patients, and CSU patients may ...
Kolkhir, P. V., Maurer, Marcus
core   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

Management Principles in Urticaria

149152In the management of patients with urticaria some basic principles should be adhered to. Identification of underlying causes should have the first priority since the elimination or avoidance of triggers is the only causal way to treat the disease ...
Zuberbier, Torsten, Grattan, Ceh E.H., Maurer, Marcus   +2 more
core   +1 more source

N‐acetylcysteine for non‐paracetamol‐induced acute liver failure in children: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Non‐surgical treatment of acute liver failure (ALF) is primarily supportive and depends on the underlying cause. While N‐acetylcysteine (NAC) is proven effective in paracetamol‐induced ALF, its potential benefits in non‐paracetamol ALF for paediatric patients remain unclear.
Alise D. E. de Groot, Désanka M. Stoppels, Arno R. Bourgonje, Willemien F. J. Hof, Martin C. J. Kneyber, Daan J. Touw, Henkjan J. Verkade, Paola Mian   +7 more
wiley   +1 more source

Acute Urticaria

5763Acute urticaria is defined as the spontaneous appearance of wheals, angioedema, or both which lasts no more than 6 weeks. The patients typically present hives only which helps to differentiate from other diseases where whealing may occur.
Zuberbier, Torsten, Zhao, Zuotao
core   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon, Chutima Seree‐aphinan, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Taweesak Maneerot, Oradawan Plong‐on, Pornsiri Sangmanee, Punthipa Nichanon, Jariya Khayman, Jiraphan Manee, Areerat Hnoonual, Kanoot Jaruthamsophon   +11 more
wiley   +1 more source